Adagio Medical Updates Investor Deck: FDA Approval Expected Q4 2026, Cash at $7.7M
ADGM sits 90% above its 52-week low of $0.363 on light trading volume (0.1× avg).
Summary
Adagio Medical filed an updated investor presentation detailing its regulatory timeline, market opportunity, and financial position, including $7.7M in cash and FDA approval expected by Q4 2026.
Key Events · Product Development and Regulatory · ADGM
-
Updated Investor Presentation Filed
Adagio Medical made available an updated corporate presentation dated August 13, 2026, for use in investor meetings.
-
FDA Approval Timeline Reaffirmed
The presentation reiterates expected FDA approval of vCLAS in Q4 2026/Q1 2027, with limited market release in 1H 2027.
-
Financial Position Disclosed
Cash and cash equivalents of $7.7M as of June 30, 2026, against $24.8M in convertible notes payable, highlighting a tight liquidity position.
-
Market Opportunity Highlighted
The presentation cites a $5.8B global VT ablation market with only 6% penetration, positioning vCLAS as a purpose-built solution.
Analysis · ADGM · Industrial Applications And Services
The updated corporate presentation provides a consolidated view of Adagio's near-term catalysts and financial position. It reiterates the FDA approval timeline for vCLAS (Q4 2026/Q1 2027) and discloses a cash balance of $7.7M against $24.8M in convertible notes, underscoring the liquidity crunch previously flagged in the Q2 10-Q. The presentation also highlights the $5.8B VT ablation market opportunity and the company's breakthrough device designation, which are central to the investment thesis.
At the time of this filing, ADGM was trading at $0.69 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $15.3M. The 52-week trading range was $0.36 to $2.58. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.